Recently, the 5th Medical Device Supply Chain Conference 2025, held in Kunming by the China IoT Medical Device Supply Chain Branch, came to a successful conclusion.

During the conference, a series of exciting speeches and forum activities attracted the attention of many participants. Among them, Mr. Liu Weimin, General Manager of Stellar Biotech Limited, shared his keynote speech on "Seizing the New Growth Pole of Southeast Asian Pharmaceutical Devices Going Global" as a guest speaker, which received warm approval from the audience.

The Southeast Asian market has shown great potential due to population growth and economic development, and is increasingly attracting attention from companies in the pharmaceutical and medical equipment industry who intend to go global.

In this keynote speech, General Manager Liu Weimin analyzed the dividends of the Southeast Asian market from multiple perspectives, including population growth and economic development, as well as geographical proximity, similar disease spectrum, and bilateral support policies.

Of course, the challenge of going global to Southeast Asia is also an unavoidable issue for enterprises. Multiple countries have multiple regulations and policy differences exist; Difficulties in localizing sales operations; The requirements for clinical trial data are also different, with high compliance risks.

This has made it difficult for many companies to expand into the Southeast Asian market. What services can Xinghan Biotechnology provide to help companies overcome difficulties and enter the Southeast Asian market to share dividends in response to the wave of medical equipment going global in Southeast Asia?

One is to provide registration and certification services to shorten the admission cycle

The second is to provide distribution and agency services for mature products, solving difficulties in localized operations

The third is to provide specialized cooperation, offering customized NPP services for tumors and rare diseases, targeted order investment cooperation, and matching the needs of pharmaceutical companies and patients.

The fourth is to provide capital co-creation services for pipeline biotech enterprises, including incubation in Singapore and introduction of clinical resources from ASEAN.

In addition to content sharing, Xinghan Biology also addressed orders as the topic of the speech.

From August 25th to 26th, 2025, Xinghan Biotechnology will customize a dual-track cooperation model of closed-door procurement matchmaking meetings and on-site visits to dialysis centers for customers with over 15 SKUs and a procurement scale of nearly 200 million yuan. The model will involve face-to-face communication with domestic enterprises.

Rich speech content and sincere intention to purchase orders. After the speech, Xinghan Biology won a warm response from the audience present. Xinghan Biotechnology hopes to take this opportunity to showcase itself and collaborate with more companies to expand its pharmaceutical and medical products to Southeast Asia, enhancing the international influence of Chinese pharmaceutical and medical brands.

Company Profile

As an innovative pharmaceutical service enterprise, Xinghan Biotechnology is committed to cross-regional introduction, research and development, production, and commercialization of global drugs/medical devices. The company focuses on providing fast product access for global pharmaceutical and medical equipment enterprises, and offering Southeast Asian (including Hong Kong and Macao) registration, certification, early market access, drug distribution, marketing and promotion services for innovative pharmaceutical and medical equipment enterprises in oncology, rare diseases, advanced diagnosis and treatment, helping patients to access global advanced medical resources faster.

The company has 30+ medical expert Key Opinion Leaders (KOLs), and 10+ commercial projects are being promoted, including innovative drugs, traditional Chinese patent medicines and simple preparations, and medical devices. It is estimated that the market product size will be 5 billion+.

July 4, 2025